Antibody-drug conjugates (ADCs) represent the next frontier in targeted cancer therapies, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. One of the most critical components in the construction of effective ADCs is the linker technology, which serves as a bridge between the antibody and the cytotoxin. A deep dive into ADC linkers reveals the complexities...
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
urdu